U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523555) titled 'Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies' on April 05.
Brief Summary: Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, includ...